Dr. Seth E. Karol, M.D.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
TN license 48545 -
Pediatrics Physician
OH license 35-097222 · TN license 48545
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $1,774 in total to this clinician.
| AbbVie Inc. | $1,500 |
|---|---|
| Jazz Pharmaceuticals Inc. | $274 |
| Consulting Fee | $1,500 |
|---|---|
| Food and Beverage | $274 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jul 30, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 3 companies. The companies reported $2,546,706 in research payments for these studies, mostly to the institutions running them.
- SJALL23H combination antigendirected induction therapy for newly diagnosed patients with bcell precursor acute lymphoblastic leukemia and lymphoma
Pfizer Inc. - A21-357;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
AbbVie Inc. - SJALL23T: Adding dasatinib or venetoclax to improve responses in children with newly diagnosed T-ALL
AbbVie Inc. - B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy
AbbVie Inc. - A24-817;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
AbbVie Inc. - A24-817;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets
AbbVie Inc. - A24-817;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets
AbbVie Inc. - A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Pos…
Amgen Inc. - A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Prec…
Amgen Inc. - A24-817;Venclexta;Carton: Venetoclax (ABT-199) 100mg Powder for Oral Suspension 4 Sachets
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.